Haplo-identical/Mismatched Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome

Advanced MDS Without Identical Sibling Donor Clinical Trial

Official title: Haplo-identical/Mismatched Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome

Status Completed

Clinical Trial Summary

Allogeneic hematopoietic stem cell transplantation (HSCT) is currently the only curative treatment for myelodysplastic syndrome (MDS), especially for advanced MDS (blast >5%). However, many patients cannot find an HLA-matched donor. haploidentical donor is an alternative stem cell source.

the study hypothesis: Haploidentical/mismatched hematopoietic stem cell transplantation can improve the survival of patients with myelodysplastic syndrome

Clinical Trial Description

n/a

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Advanced MDS Without Identical Sibling Donor
• Myelodysplastic Syndromes
• Preleukemia

• NCT number: NCT01793675
• Study type: Observational
• Source: Peking University People's Hospital
• Status: Completed
• Phase: N/A
• Start date: April 2003
• Completion date: December 2014